Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in non-radiographic axial spondyloarthritis (China, Phase 3)
CTR20211320Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in axial spondyloarthritis (axSpA), sponsored by Novartis. Started Jun 2021; status: completed.
02
Drugs
secukinumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on CTR20211320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211320.